X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (347) 347
index medicus (336) 336
male (195) 195
heterocyclic compounds, 3-ring - pharmacology (169) 169
animals (168) 168
female (168) 168
heterocyclic compounds, 3-ring - pharmacokinetics (155) 155
adult (126) 126
heterocyclic compounds, 3-ring - administration & dosage (126) 126
pharmacology & pharmacy (122) 122
hiv infections - drug therapy (121) 121
heterocyclic compounds, 3-ring - therapeutic use (116) 116
middle aged (108) 108
mice (80) 80
heterocyclic compounds, 3-ring - adverse effects (77) 77
raltegravir (76) 76
pharmacokinetics (74) 74
rats (71) 71
dolutegravir (70) 70
infectious diseases (68) 68
double-blind (66) 66
heterocyclic compounds, 3-ring - chemistry (64) 64
hiv (64) 64
aged (60) 60
treatment outcome (57) 57
dose-response relationship, drug (54) 54
chemistry, medicinal (53) 53
drug therapy (53) 53
structure-activity relationship (53) 53
hiv-1 - drug effects (51) 51
hiv integrase inhibitors - pharmacokinetics (50) 50
antiviral agents (48) 48
heterocyclic compounds, 3-ring - chemical synthesis (48) 48
once-daily dolutegravir (48) 48
analysis (46) 46
drug interactions (46) 46
hiv infections - virology (45) 45
oncology (45) 45
hiv integrase inhibitors - therapeutic use (43) 43
young adult (43) 43
administration, oral (42) 42
immunology (41) 41
therapy (41) 41
antiretroviral-naive adults (40) 40
heterocyclic compounds, 3-ring - blood (40) 40
drug administration schedule (39) 39
article (38) 38
human immunodeficiency virus--hiv (38) 38
infection (38) 38
cancer (37) 37
hiv integrase inhibitors - pharmacology (37) 37
hiv infection (36) 36
microbiology (36) 36
cell line, tumor (35) 35
hiv integrase inhibitors - administration & dosage (35) 35
research (35) 35
safety (35) 35
drug therapy, combination (34) 34
simeprevir (34) 34
anti-hiv agents - administration & dosage (33) 33
clinical trials (32) 32
adolescent (31) 31
antiretroviral drugs (31) 31
health aspects (31) 31
mutation (31) 31
aids/hiv (30) 30
area under curve (30) 30
integrase inhibitor (30) 30
anti-hiv agents - therapeutic use (29) 29
care and treatment (29) 29
hiv integrase inhibitors - adverse effects (29) 29
proto-oncogene proteins c-akt - antagonists & inhibitors (29) 29
resistance (29) 29
drug combinations (28) 28
chemistry, organic (27) 27
pharmacology/toxicology (27) 27
abridged index medicus (26) 26
drug resistance, viral (26) 26
integrase (25) 25
medicine & public health (25) 25
molecular structure (25) 25
pharmacology (25) 25
rna, viral - blood (25) 25
viral load (25) 25
activation (24) 24
antiretroviral therapy (24) 24
efficacy (24) 24
virology (24) 24
anti-hiv agents - pharmacokinetics (23) 23
clinical trials as topic (23) 23
toxicology (23) 23
dogs (22) 22
elvitegravir (22) 22
initial treatment (22) 22
internal medicine (22) 22
rats, sprague-dawley (22) 22
s/gsk1349572 (22) 22
xenograft model antitumor assays (22) 22
antineoplastic agents - pharmacology (21) 21
antiviral agents - therapeutic use (21) 21
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 01/2013, Volume 62, Issue 1, pp. 21 - 27
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2014, Volume 20, Issue 22, pp. 5672 - 5685
Journal Article
Nature Communications, ISSN 2041-1723, 12/2018, Volume 9, Issue 1, pp. 2 - 12
Journal Article
Gastroenterology, ISSN 0016-5085, 2010, Volume 138, Issue 3, pp. 913 - 921
Background & Aims The search for targeted anti-hepatitis C virus (HCV) drugs is driven by the adverse effect profile and limited efficacy of the current... 
Gastroenterology and Hepatology | HCV | Phase-1 Study | Protease Inhibitor | TMC435 | PLUS RIBAVIRIN | INTERFERON-ALPHA-2B | VIRUS | TELAPREVIR | SAFETY | GENOTYPES 1 | INFECTED INDIVIDUALS | THERAPY | PEGINTERFERON ALPHA-2A | GASTROENTEROLOGY & HEPATOLOGY | Simeprevir | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | DNA, Viral - analysis | Male | RNA, Viral - blood | Young Adult | Time Factors | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Hepacivirus - drug effects | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Viral Nonstructural Proteins - genetics | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Hepatitis C - diagnosis | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Sulfonamides - adverse effects | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sulfonamides - administration & dosage | Medical colleges | Medical research | Protease inhibitors | Proteases | Interferon alpha | Medicine, Experimental | Biological response modifiers | Hepatitis C
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2014, Volume 59, Issue 7, pp. 1032 - 1037
Journal Article